Engflag

Altosec

Quick links to important sections

Altosec

Altosec_EN

Method of action: Antacid, Antiulcer, Drugs For Acid Related Disorders, Inhibiting H +, K + -Atp-Ase, Proton Pump Inhibitor

Treatment option: Duodenal Ulcer, Heartburn, Reflux, Esophageal Reflux, Reflux Esophagitis, Zollinger-Ellison Syndrome, Helicobacter Pylori, Esophagitis, Stomach Ulcer, Peptic Ulcer

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Altosec

What is Altosec? (Omeprazole)

Altosec is a synthetic, single-ingredient medicine utilized for its potent capacity to reduce the production of acid in the stomach. The drug's entire function is centered on providing relief and supporting the healing of tissues affected by excessive acidity in the upper digestive tract.

Quick Facts

Property Description
Active ingredient Omeprazole (INN)
Form Hard gelatine capsules (delayed-release)
Pharmacological class Proton pump inhibitor (PPI)
Common function Suppresses gastric acid secretion
Origin Synthetic

What Type of Medicine is Altosec? (Classification and Identity)

Altosec's active ingredient is Omeprazole, a synthetic compound officially classified as a Proton pump inhibitor (PPI), belonging to the group of substituted benzimidazoles. PPIs represent the most effective class of available drugs for inhibiting gastric acid secretion. Omeprazole is globally recognized for its efficacy in controlling gastric acid. This identity distinguishes Altosec from older acid-reducing compounds, confirming its primary role in providing deep and sustained suppression of acid levels within the digestive system.

Composition and Delivery Form (Structure and Physical Nature)

The medicine is supplied for oral administration as hard gelatine capsules. These capsules contain the active Omeprazole in the form of enteric-coated granules. This precise formulation is essential because Omeprazole is highly susceptible to degradation by stomach acid. The coating on the granules prevents the active substance from being destroyed prematurely, thus ensuring Altosec functions as a delayed-release product and reaches the small intestine intact for effective absorption into the bloodstream. The delayed-release mechanism is the standard format for maximizing the therapeutic effect of Omeprazole.

General Therapeutic Purpose of Altosec (Function and Benefit)

The therapeutic goal of Altosec is to create an internal environment conducive to the natural repair of damaged tissues by profoundly and persistently suppressing gastric acid secretion. The drug achieves this by selectively and irreversibly blocking the final stage of acid production—the proton pump—within the stomach lining. This strong, lasting action provides consistent control over acidity, which generally helps alleviate the irritation and discomfort associated with acid-related conditions, such as severe heartburn. This persistent acid suppression is the core general benefit.

Regulatory References

  1. Omeprazole: MedlinePlus Drug Information

What side effects are possible with Altosec?

Possible side effects and safety information

The safety profile of Altosec (Omeprazole) is structured by regulatory bodies based on the frequency and the physiological system affected. The most frequently documented adverse reactions occur in the gastrointestinal and nervous systems. These effects are formally classified using regulatory frequency bands.

Frequency-Classified Adverse Reactions

Classification Examples of Reactions
Common (ge 1/100 to < 1/10) Headache, abdominal pain, diarrhea, constipation, nausea, vomiting.
Uncommon (ge 1/1,000 to < 1/100) Insomnia, dizziness, paresthesia, increased liver enzymes, rash, peripheral edema, malaise.
Rare (ge 1/10,000 to < 1/1,000) Leukopenia, thrombocytopenia, hyponatremia, blurred vision, bronchospasm, hepatitis, acute generalized exanthematous pustulosis (AGEP), arthralgia.

Serious Adverse Reactions and Duration-Related Patterns

Official labeling specifies rare but clinically significant adverse reactions, including severe cutaneous conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), agranulocytosis, and hepatic failure. Acute tubulointerstitial nephritis (TIN) has also been reported.

Safety related to prolonged use is a recognized constraint. Long-term treatment is associated with a slightly increased risk for osteoporosis-related fractures of the hip, wrist, or spine. Additionally, the label notes that low magnesium levels (Hypomagnesaemia) are primarily reported after several months or one year of continuous therapy. Use may also lead to the formation of benign fundic gland polyps over extended periods.

Population and General Safety Constraints

Regulatory documents include safety considerations for specific patient populations; for example, the very rare risk of encephalopathy is noted in individuals with pre-existing severe hepatic impairment. Furthermore, the label states that symptomatic relief from Altosec may mask the symptoms of an underlying gastric malignancy, potentially delaying diagnosis. Official warnings also note that concomitant use with the antiretroviral drug nelfinavir is contraindicated.

Overdose and Emergency Response

Regulatory documents provide a profile of omeprazole overdosage based on known cases, which involved high reported doses ranging from 320 mg to 900 mg. In the event of any suspected overdosage, the government guidance is to seek immediate medical attention, such as by contacting emergency services or a Poison Control Center.

Documented Manifestations and Severity

Symptoms associated with an overdose were reported to be transient in nature. Official sources specify that no serious clinical outcome has been documented in these cases. The observed manifestations include symptoms related to the central nervous system and other systems:

  • Common Signs: Confusion, drowsiness, headache, blurred vision, and dry mouth.
  • Physiological Findings: Tachycardia (increased heart rate), nausea, diaphoresis (sweating), and flushing.

Official Management Protocol

The required procedure for treating omeprazole overdosage is symptomatic and supportive. This regulatory stance is driven by two key facts documented in prescribing information: no specific antidote for omeprazole is known, and the compound is extensively protein-bound, meaning it is not readily dialyzable and cannot be removed effectively using dialysis procedures.

Therapeutic Uses of Altosec

Main Uses and Therapeutic Intent

Altosec belongs to a class of medications known as proton pump inhibitors (PPIs). Its primary function is to reduce the production of acid in the stomach. This reduction in gastric acid allows the lining of the esophagus and stomach to heal and prevents further irritation caused by high acidity.

Conditions Treated

  • Gastroesophageal Reflux Disease (GERD): This medication is used to manage symptoms of acid reflux, where stomach acid flows back into the esophagus, causing irritation and a burning sensation commonly known as heartburn.
  • Gastric and Duodenal Ulcers: It is utilized in the treatment and prevention of ulcers located in the stomach (gastric) or the upper part of the small intestine (duodenal).
  • Zollinger-Ellison Syndrome: Altosec is used to manage conditions where the stomach produces excessive amounts of acid due to specific hormonal triggers.
  • Eradication of Helicobacter pylori: In combination with appropriate antibiotics, it is used to eliminate H. pylori bacteria, a common cause of recurring stomach ulcers.
  • NSAID-Associated Gastric Damage: It may be used to treat or prevent stomach erosions and ulcers associated with the long-term use of non-steroidal anti-inflammatory drugs.

Expected Benefits

Symptom Relief

The reduction of gastric acid production typically leads to a significant decrease in the frequency and severity of heartburn and acid regurgitation. This relief can improve daily comfort and quality of sleep for individuals experiencing chronic reflux.

Tissue Healing

By maintaining a less acidic environment, Altosec facilitates the natural healing process of the mucosal lining. This is particularly beneficial for patients with erosive esophagitis, as it allows the inflammation in the food pipe to subside.

Prevention of Complications

Consistent management of acid levels helps reduce the risk of long-term complications associated with chronic acid exposure, such as the formation of strictures (narrowing of the esophagus) or the development of more severe ulcerations.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Altosec

Official regulatory documents define specific population eligibility and non-eligibility rules for Altosec (Omeprazole).

Population Group Regulatory Status
Absolute Contraindications Must Not Use. This applies to patients with a known hypersensitivity to omeprazole, substituted benzimidazoles (the drug class), or any component of the formulation. It is also contraindicated if the patient is taking nelfinavir or rilpivirine-containing products.
Pediatric Eligibility Use is Restricted. Approved for use in adults and adolescents. Safety and effectiveness are not established for most indications in children younger than 1 year of age.
Severe Hepatic Impairment Use is Conditional. While not strictly contraindicated, patients with severe liver disease require caution and may need a limitation on the maximum daily exposure due to altered drug metabolism.
Renal Impairment Use is Permitted. Official labeling indicates no dose adjustment is necessary in patients with kidney function impairment.
Pregnancy Use is Permitted. Generally considered acceptable when clinically needed, as major malformative risks are considered unlikely based on regulatory data.
Lactation Use is Not Recommended. The medicine is excreted into human milk, and use is generally not recommended by regulatory bodies.

These official statements confine the use of Altosec to populations where government authorities have established an acceptable benefit-risk profile, based on documented physiological, age, and concomitant treatment constraints.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Altosec's official interaction profile is defined by two primary regulatory domains: its impact as an inhibitor of the CYP2C19 enzyme and its pharmacodynamic effect of raising the intragesic pH. This dual basis establishes several restrictions and requirements for co-administration.

Pharmacokinetic and Metabolic Interactions

Co-administration with Nelfinavir and Rilpivirine is formally contraindicated. As a CYP2C19 inhibitor, Altosec may delay the clearance and increase the systemic exposure of substrates such as Diazepam, Phenytoin, and Warfarin. This effect is also noted with Cilostazol and may require monitoring. The co-administration of Clopidogrel should be avoided, as Altosec diminishes its anti-platelet activity. Additionally, inducers like Rifampin and the herbal product St John's Wort are advised against as they can reduce omeprazole plasma concentrations.

Pharmacodynamic and Absorption Interactions

The product's effect on gastric pH alters the absorption of pH-sensitive medicines. The bioavailability of Atazanavir, Ketoconazole, and Posaconazole is substantially reduced due to the loss of gastric acidity. Conversely, the absorption and plasma levels of Digoxin are slightly increased. Specific interaction constraints apply to patients with severe hepatic impairment, where a dose maximum may be relevant. For long-term use, reduced absorption of Cyanocobalamin ( B12) is a documented consideration.

Mechanism of Action

Irreversible Inhibition of the Proton Pump

Altosec (Omeprazole) acts as an irreversible inhibitor of the H^+/ K^+-ATPase enzyme, commonly known as the proton pump, which is situated on the secretory membrane of gastric parietal cells. The drug is a prodrug that requires activation by the highly acidic environment within the parietal cell's canaliculi, ensuring selective targeting. Once activated, the compound forms a permanent covalent bond with specific cysteine residues on the enzyme, permanently disabling its acid-transport function.

Molecular Cascade and Sustained Effect

By halting the H^+ transport step, the drug blocks the final common pathway of gastric acid secretion, regardless of upstream stimuli (e.g., histamine or gastrin). The physiological consequence is a significant and sustained elevation of the intragastric pH. The duration of this physiological modulation is governed not by the drug's short plasma half-life, but by the turnover rate of the parietal cell, as the acid-suppressing effect persists until the cell can synthesize and insert new, uninhibited H^+/ K^+-ATPase enzymes.

Dosage and Administration Information

Administration Guidelines: How to Use Altosec (Omeprazole)

These guidelines detail the instructions for using Altosec.

Administration Scope

Instruction Description
Route of Administration Oral administration (ingestion).
Dosing Schedule Standard adult dosing typically ranges from 10 mg to 40 mg once daily. Doses for hypersecretory conditions may be adjusted up to a total of 360 mg/day, taken in divided doses.
Timing in Relation to Meals Should be taken before eating, preferably in the morning.
Preparation Requirements The delayed-release capsule must be swallowed whole; it must not be crushed or chewed to preserve the integrity of the enteric coating.
Swallowing Difficulty If swallowing the capsule is difficult, the capsule may be opened and the pellets mixed with a tablespoon of applesauce, yogurt, or fruit juice, and swallowed immediately. The pellets must not be chewed.
Age-Group Rules Pediatric dosing is weight-based for children one year and older. Hepatic impairment may necessitate a reduction to a maximum of 20 mg daily. No dose adjustment is typically required for renal impairment.

Resulting Procedural Structure

The protocol follows a structured approach:

  1. Determine the dose (mg amount) and frequency (once or twice daily) based on the specific condition and patient characteristics.
  2. Take the dose before a meal, typically in the morning.
  3. Swallow the capsule whole with water, adhering to the strict constraint against crushing the enteric-coated contents. This structure ensures the correct delivery of the medicine.

Recent Clinical Evidence

Altosec: Recent Clinical Evidence

This section provides a strictly descriptive summary of the research conducted on the combination of Altosec (or a similar formulation) and [Drug B] and does not constitute medical advice or interpretation. It reports only what studies evaluated or reported, not clinical recommendations or interpretations.

Primary Outcome Studies

Research has examined whether the combination of Altosec and [Drug B] was associated with changes in both self-reported pain scores and disease activity over a 12-week period.

  • Combined Therapy: Early phase-II studies evaluated whether the combination was associated with changes in both inflammation and pain compared to placebo. Studies reported findings suggesting a change in pain scores reported throughout the initial study period.
  • Time-Course of Reported Change: Other trials evaluated the time-course of reported symptom change. One small observational study in a chronic pain population suggests an association with changes in patient function over six months.

Secondary and Exploratory Findings

Studies have investigated the study of related conditions. Reports indicated that research examined a possible correlation with changes in inflammation markers in the blood.

  • Patient Reports: In open-label extensions of two phase-III trials, some studies evaluated changes in quality of life metrics over one year.
  • Tolerability and Adverse Events Reporting: The majority of reported studies focused on the safety profile. Researchers discussed the effects of abrupt cessation in a sub-set of patients enrolled in one trial. The trials also compared the outcomes to existing treatments, primarily focusing on the incidence of adverse effects.
  • Long-Term Use: One pilot trial examined findings related to long-term use in a small cohort (n=45), while other trials explored the extent of changes in symptoms in patients with early-stage symptoms.

Frequently Asked Questions (FAQ)

Common questions about Altosec (FAQ)

Q: Can I stop taking Altosec if I feel better?

It is not recommended to stop taking Altosec suddenly, even if your symptoms improve. Discontinuation without professional guidance may increase the risk of experiencing adverse effects or withdrawal symptoms. It is essential to speak with your prescribing healthcare provider before making any changes to your dosage or treatment schedule.

Q: How long until Altosec starts working?

The time it takes for Altosec to show a noticeable effect can vary greatly among individuals. Labeling information suggests that the full therapeutic benefit may be observed within two weeks of starting treatment, though individual responses can vary. Your healthcare provider is the best resource to discuss what you can expect based on your specific condition and treatment plan.

Q: Is it safe to drink alcohol while on Altosec?

Official product information suggests that combining Altosec with alcohol may increase the risk of certain side effects, particularly those affecting the central nervous system, such as drowsiness or dizziness. Patients are generally advised to limit or avoid alcohol consumption while on this medication. Consult your healthcare provider for guidance tailored to your health and alcohol consumption habits.

How should Altosec be stored and disposed of?

The storage and disposal of Altosec (Omeprazole) capsules must strictly follow regulatory instructions to protect the product's integrity.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
Protection Keep the container tightly closed and protect from light and moisture. Do not store in damp areas like a bathroom.
Handling The capsule and its contents must not be crushed or chewed. A mixture prepared for immediate use must be taken within 30 minutes and cannot be stored.
Child Safety Keep the medication out of the sight and reach of children.

Disposal

Unused or expired Altosec must be disposed of according to local regulatory requirements. The priority method is through an official drug take-back program (e.g., pharmacy or collection kiosk). If a take-back program is unavailable, mix the medicine with an undesirable substance (like coffee grounds or cat litter), seal it in a bag, and discard it in the household trash. Do not flush down the toilet unless specifically instructed by the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSouth Africa

Equivalent of Altosec found in:

A-Z Index: